XOMA Royalty Corp
XOMADelisted Jul 14, 2026- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000791908
XOMA Royalty Corp was delisted on Jul 14, 2026; its insiders filed their last Form 4 on Jul 16, 2026; 98 institutions reported holding it in 13F filings for Q2 2026, worth $723.7M in total; no superinvestor held it.
Holders of 5% or more of XOMA
Holders whose latest Schedule 13D or 13G filing reports 5% or more of XOMA Royalty Corp, largest stake first. The change is against the holder's previous filing.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Ligand Pharmaceuticals Inc | 13D | 47.00%8.06M shares | New | May 1, 20261 filing | May 1, 2026 | SEC |
| Biotechnology Value Fund L P | 13D/A | 43.30%7.59M shares | +21.90 ppfrom 21.40% | Jan 28, 20254 filings | May 18, 2026 | SEC |
| Morgan Stanley | 13G/A | 13.70%1.70M shares | +1.00 ppfrom 12.70% | May 7, 20253 filings | Feb 12, 2026 | SEC |
| FMR LLC | 13G/A | 10.20%1.27M shares | +1.20 ppfrom 9.00% | Aug 6, 20252 filings | Mar 6, 2026 | SEC |
| BlackRock, Inc. | 13G | 5.40%640.5K shares | New | Apr 27, 20261 filing | Apr 27, 2026 | SEC |
| Woodline Partners LP | 13G | 5.40%640.0K shares | New | May 15, 20261 filing | May 15, 2026 | SEC |
| Vanguard Capital Management LLC | 13G | 5.15%613.5K shares | New | Apr 30, 20261 filing | Apr 30, 2026 | SEC |
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
15 Schedule 13D and 13G filings on XOMA Royalty Corp, newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Aug 7, 20265:32 PM ET | Morgan Stanleyand 1 other | 13G/A | 0.00%0 shares | −9.50 ppfrom 9.50%Below 5% | Jul 31, 2026 | SEC |
| Aug 7, 20265:28 PM ET | Morgan Stanleyand 1 other | 13G/A | 9.50%1.69M shares | −4.20 ppfrom 13.70% | Jun 30, 2026 | SEC |
| Aug 7, 202611:07 AM ET | FMR LLCand 1 other | 13G/A | 0.00%0 shares | −9.10 ppfrom 9.10%Below 5% | Jul 31, 2026 | SEC |
| Aug 6, 202610:48 AM ET | FMR LLCand 1 other | 13G/A | 9.10%1.61M shares | −1.10 ppfrom 10.20% | Jun 30, 2026 | SEC |
| Jul 31, 202610:47 AM ET | Vanguard Capital Management LLC | 13G/A | 3.23%571.8K shares | −1.92 ppfrom 5.15%Below 5% | Jun 30, 2026 | SEC |
| Jul 30, 202611:18 AM ET | BlackRock, Inc. | 13G/A | 3.90%685.8K shares | −1.50 ppfrom 5.40%Below 5% | Jun 30, 2026 | SEC |
| Jul 16, 20265:00 PM ET | Biotechnology Value Fund L Pand 9 others | 13D/A | 0.00%0 shares | −43.30 ppfrom 43.30%Below 5% | Jul 14, 2026 | SEC |
| May 18, 20265:26 PM ET | Biotechnology Value Fund L Pand 9 others | 13D/A | 43.30%7.59M shares | +21.90 ppfrom 21.40% | May 14, 2026 | SEC |
| May 15, 20269:03 AM ET | Woodline Partners LP | 13G | 5.40%640.0K shares | New | Mar 31, 2026 | SEC |
| May 1, 20269:15 PM ET | Ligand Pharmaceuticals Inc | 13D | 47.00%8.06M shares | New | Apr 27, 2026 | SEC |
| Apr 30, 20262:38 PM ET | Vanguard Capital Management LLC | 13G | 5.15%613.5K shares | New | Mar 31, 2026 | SEC |
| Apr 29, 20265:43 PM ET | Biotechnology Value Fund L Pand 9 others | 13D/A | 21.40%2.59M shares | −0.20 ppfrom 21.60% | Apr 27, 2026 | SEC |
| Apr 27, 20264:12 PM ET | BlackRock, Inc. | 13G | 5.40%640.5K shares | New | Mar 31, 2026 | SEC |
| Mar 27, 20262:14 PM ET | Vanguard Group Inc | 13G/A | 0.00%0 shares | −5.33 ppfrom 5.33%Below 5% | Mar 13, 2026 | SEC |
| Mar 6, 202610:05 AM ET | FMR LLCand 1 other | 13G/A | 10.20%1.27M shares | +1.20 ppfrom 9.00% | Feb 27, 2026 | SEC |
| Feb 12, 20262:36 PM ET | Morgan Stanleyand 1 other | 13G/A | 13.70%1.70M shares | +1.00 ppfrom 12.70% | Dec 31, 2025 | SEC |
| Aug 6, 202512:19 PM ET | FMR LLCand 1 other | 13G/A | 9.00%1.08M shares | – | Jun 30, 2025 | SEC |
| Jul 29, 20252:54 PM ET | Vanguard Group Inc | 13G | 5.33%638.8K shares | New | Jun 30, 2025 | SEC |
| Jun 6, 20254:14 PM ET | Morgan Stanleyand 1 other | 13G/A | 12.70%1.53M shares | +3.40 ppfrom 9.30% | May 30, 2025 | SEC |
| May 20, 20256:52 PM ET | Biotechnology Value Fund L Pand 9 others | 13D/A | 21.60%2.59M shares | −3.70 ppfrom 25.30% | May 16, 2025 | SEC |
| May 7, 202511:35 AM ET | Morgan Stanleyand 1 other | 13G | 9.30%1.11M shares | New | Mar 31, 2025 | SEC |
| Jan 28, 20255:19 PM ET | Biotechnology Value Fund L Pand 9 others | 13D/A | 25.30%2.98M shares | – | Jan 24, 2025 | SEC |
| Feb 9, 2023 | FMR LLC | 13G/AOld format | – | – | – | SEC |
| Aug 10, 2022 | FMR LLC | 13G/AOld format | – | – | – | SEC |
| Feb 14, 2022 | Eagle Point Credit Management LLC | 13G/AOld format | – | – | – | SEC |
| Feb 9, 2022 | FMR LLC | 13GOld format | – | New | – | SEC |
| Apr 19, 2021 | Eagle Point Credit Management LLC | 13GOld format | – | New | – | SEC |
| Apr 2, 2021 | Biotechnology Value Fund L P | 13D/AOld format | – | – | – | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell XOMA Royalty Corp shares.
No Form 144 notices for XOMA Royalty Corp are on file.